Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free ICCM Stock Alerts

IceCure Medical (ICCM) Competitors

IceCure Medical logo
$2.43 -0.02 (-0.82%)
As of 08/21/2026 04:00 PM Eastern
Compare

ICCM vs. BDMD, SNWV, POCI, MLSS, and NSPR

Should you buy IceCure Medical stock or one of its competitors? IceCure Medical's main competitors and comparable companies include Baird Medical Investment (BDMD), Sanuwave Health (SNWV), Precision Optics (POCI), Milestone Scientific (MLSS), and InspireMD (NSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does IceCure Medical compare to Baird Medical Investment?

Baird Medical Investment (NASDAQ:BDMD) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Baird Medical Investment has a beta of -1.16, meaning that its stock price is 216% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Baird Medical Investment has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Baird Medical Investment's return on equity of 0.00% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
IceCure Medical -427.67%-174.26%-112.58%

In the previous week, IceCure Medical had 6 more articles in the media than Baird Medical Investment. MarketBeat recorded 11 mentions for IceCure Medical and 5 mentions for Baird Medical Investment. Baird Medical Investment's average media sentiment score of 0.21 beat IceCure Medical's score of -0.64 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Baird Medical Investment
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IceCure Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 2,060.49%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Baird Medical Investment has higher revenue and earnings than IceCure Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.11N/AN/AN/A
IceCure Medical$3.95M2.11-$15.06M-$8.52N/A

Summary

Baird Medical Investment beats IceCure Medical on 7 of the 13 factors compared between the two stocks.

How does IceCure Medical compare to Sanuwave Health?

IceCure Medical (NASDAQ:ICCM) and Sanuwave Health (NASDAQ:SNWV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Sanuwave Health has a net margin of 32.38% compared to IceCure Medical's net margin of -427.67%. Sanuwave Health's return on equity of 1,728.10% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-427.67% -174.26% -112.58%
Sanuwave Health 32.38%1,728.10%39.04%

IceCure Medical presently has a consensus price target of $52.50, suggesting a potential upside of 2,060.49%. Sanuwave Health has a consensus price target of $51.00, suggesting a potential upside of 1,006.29%. Given IceCure Medical's higher possible upside, equities research analysts plainly believe IceCure Medical is more favorable than Sanuwave Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Sanuwave Health
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, IceCure Medical had 11 more articles in the media than Sanuwave Health. MarketBeat recorded 11 mentions for IceCure Medical and 0 mentions for Sanuwave Health. Sanuwave Health's average media sentiment score of 0.00 beat IceCure Medical's score of -0.64 indicating that Sanuwave Health is being referred to more favorably in the news media.

Company Overall Sentiment
IceCure Medical Negative
Sanuwave Health Neutral

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 14.4% of Sanuwave Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IceCure Medical has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Sanuwave Health has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.95M2.11-$15.06M-$8.52N/A
Sanuwave Health$44.02M0.90$11.81M$0.2419.21

Summary

Sanuwave Health beats IceCure Medical on 13 of the 17 factors compared between the two stocks.

How does IceCure Medical compare to Precision Optics?

IceCure Medical (NASDAQ:ICCM) and Precision Optics (NASDAQ:POCI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 13.7% of Precision Optics shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 14.4% of Precision Optics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precision Optics has a net margin of -17.03% compared to IceCure Medical's net margin of -427.67%. Precision Optics' return on equity of -37.47% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-427.67% -174.26% -112.58%
Precision Optics -17.03%-37.47%-19.96%

IceCure Medical has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

IceCure Medical presently has a consensus target price of $52.50, indicating a potential upside of 2,060.49%. Given IceCure Medical's stronger consensus rating and higher possible upside, research analysts clearly believe IceCure Medical is more favorable than Precision Optics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Precision Optics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, IceCure Medical had 8 more articles in the media than Precision Optics. MarketBeat recorded 11 mentions for IceCure Medical and 3 mentions for Precision Optics. Precision Optics' average media sentiment score of 0.00 beat IceCure Medical's score of -0.64 indicating that Precision Optics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IceCure Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
Precision Optics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Precision Optics has higher revenue and earnings than IceCure Medical. Precision Optics is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.95M2.11-$15.06M-$8.52N/A
Precision Optics$28.94M1.72-$5.78M-$0.63N/A

Summary

Precision Optics beats IceCure Medical on 9 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Milestone Scientific has a net margin of -52.01% compared to IceCure Medical's net margin of -427.67%. Milestone Scientific's return on equity of -60.26% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
IceCure Medical -427.67%-174.26%-112.58%

Milestone Scientific presently has a consensus target price of $1.00, indicating a potential upside of 107.99%. IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,060.49%. Given IceCure Medical's higher possible upside, analysts plainly believe IceCure Medical is more favorable than Milestone Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, IceCure Medical had 11 more articles in the media than Milestone Scientific. MarketBeat recorded 11 mentions for IceCure Medical and 0 mentions for Milestone Scientific. Milestone Scientific's average media sentiment score of 0.00 beat IceCure Medical's score of -0.64 indicating that Milestone Scientific is being referred to more favorably in the media.

Company Overall Sentiment
Milestone Scientific Neutral
IceCure Medical Negative

Milestone Scientific has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Milestone Scientific has higher revenue and earnings than IceCure Medical. Milestone Scientific is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$9.42M4.53-$6.93M-$0.04N/A
IceCure Medical$3.95M2.11-$15.06M-$8.52N/A

Summary

Milestone Scientific beats IceCure Medical on 12 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to InspireMD?

IceCure Medical (NASDAQ:ICCM) and InspireMD (NYSE:NSPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

IceCure Medical has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

IceCure Medical has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.95M2.11-$15.06M-$8.52N/A
InspireMD$10.84M3.86-$19.92M-$0.64N/A

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 25.0% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, IceCure Medical had 9 more articles in the media than InspireMD. MarketBeat recorded 11 mentions for IceCure Medical and 2 mentions for InspireMD. InspireMD's average media sentiment score of 0.25 beat IceCure Medical's score of -0.64 indicating that InspireMD is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IceCure Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
InspireMD
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

IceCure Medical currently has a consensus price target of $52.50, suggesting a potential upside of 2,060.49%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 400.11%. Given IceCure Medical's higher possible upside, equities analysts clearly believe IceCure Medical is more favorable than InspireMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
InspireMD
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

InspireMD has a net margin of -413.96% compared to IceCure Medical's net margin of -427.67%. InspireMD's return on equity of -69.42% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-427.67% -174.26% -112.58%
InspireMD -413.96%-69.42%-57.68%

Summary

InspireMD beats IceCure Medical on 11 of the 15 factors compared between the two stocks.

Get IceCure Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICCM vs. The Competition

Export
MetricIceCure MedicalHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.40M$5.89B$7.27B$12.76B
Dividend YieldN/A1.75%2.54%11.08%
P/E Ratio-0.2926.30270.6924.20
Price / Sales2.1180.78639.89109.35
Price / CashN/A33.2076.8953.23
Price / Book0.706.2013.436.37
Net Income-$15.06M$149.51M$3.46B$347.74M
7 Day Performance-19.54%0.87%2.15%0.06%
1 Month Performance-27.03%8.29%6.18%2.86%
1 Year Performance-90.82%7.70%24.96%17.13%

IceCure Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICCM
IceCure Medical
2.8654 of 5 stars		$2.43
-0.8%		$52.50
+2,060.5%		-90.7%$8.40M$3.95MN/A60
BDMD
Baird Medical Investment
1.1698 of 5 stars		$1.17
-4.1%		N/A-42.0%$47.95M$22.54MN/AN/A
SNWV
Sanuwave Health
3.1373 of 5 stars		$5.50
-4.0%		$51.00
+827.3%		-88.8%$47.30M$44.05M22.9240
POCI
Precision Optics
0.1304 of 5 stars		$4.24
flat		N/A-1.7%$46.39M$19.09MN/A80
MLSS
Milestone Scientific
1.4695 of 5 stars		$0.49
+2.4%		$1.00
+105.6%		-19.1%$43.02M$8.90MN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ICCM) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel